Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
2.065
-0.010 (-0.48%)
At close: Oct 23, 2026, 4:00 PM EDT
2.260
+0.195 (9.44%)
After-hours: Oct 23, 2026, 7:50 PM EDT
Ernexa Therapeutics Employees
As of December 31, 2025, Ernexa Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year. That makes Ernexa Therapeutics the 41,130th largest employer in the world and 6,272nd in the United States.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,753,429
Market Cap
3.37M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% | 5 | 2 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 6 | 0 |
| Dec 31, 2023 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2022 | 9 | -1 | -10.00% | 9 | 0 |
| Dec 31, 2021 | 10 | 0 | - | 10 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Enlivex | 34 |
| Aptevo Therapeutics | 33 |
| Dermata Therapeutics | 9 |
| Eocene | 6 |
| KALA BIO | 6 |
| Cadrenal Therapeutics | 5 |
| GRI Bio | 4 |
| Addex Therapeutics | 3 |
ERNA News
- 2 days ago - Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment - GlobeNewsWire
- 12 days ago - Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - GlobeNewsWire
- 18 days ago - Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center - GlobeNewsWire
- 23 days ago - Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic - GlobeNewsWire
- 24 days ago - Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101 - TheFly
- 24 days ago - Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND - GlobeNewsWire
- 25 days ago - Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting - TheFly
- 25 days ago - Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy - GlobeNewsWire